- €43.63bn
- €77.10bn
- €45.58bn
Bayer CEO says company now in a better position to make strategic choices
Live Markets: Rhine levels fall, growth risks rise
Bayer rises after Q2 beat, reduced debt outlook
Bayer posts unexpected gain in adjusted profit on seed demand (updated)
Bayer's Q2 sales rise 2.2%, core EPS down 16.7%
Bayer posts unexpected 1.9% gain in Q2 adjusted EBITDA
Drugmakers, retailers must face 'maximum strength' claim in decongestant false ad litigation in US
Brief: Bayer Submits Application For Next Indication Of Kerendia In China
Brief: Bayer And Henry Ford Health Announce Strategic Research Partnership
Brief: Bayer Signs Licensing Agreement With RAGT
Brief: Bayer AG - Sabanto And Leaps By Bayer Announce Oversubscribed Series B Financing To Scale Autonomous Technology For Row Crop Farming
Analysis: Pesticide makers stack wins against US environmental, public health groups
Bayer gets €3 billion in Apollo deal for contraceptives unit (updated)
Bayer gets €3 billion in Apollo deal for LARC stake
Brief: Bayer Secures 3 Bln EUR To Improve Capital Structure
Bayer seeks to end federal Roundup litigation after Supreme Court win
HSBC says European healthcare can benefit if AI, tech weaken
DB upgrades Bayer to 'buy' as U.S. court ruling eases glyphosate concerns
Bayer fuels break-up talk as Roundup placed in separate business (updated)